Efficacy of Upadacitinib in Treating Alopecia Areata, Atopic Dermatitis, and Th1 Comorbidities in Pediatric Patients: A Comprehensive Case Series and Literature Review

This study explores the use of upadacitinib, a selective JAK1 inhibitor, in treating three adolescent patients with refractory alopecia areata (AA) and atopic dermatitis (AD) over 12 months. The patients experienced rapid remission of AD symptoms and significant hair regrowth, with improved SALT scores at six and twelve months, and no severe adverse events. One patient achieved complete hair regrowth despite having ophiasis, a typically poor prognosis pattern. The study highlights the novelty of using upadacitinib in pediatric cases, as only four previous cases were identified in the literature. The findings suggest upadacitinib as a safe and effective treatment for pediatric patients with AA and AD, especially those unresponsive to conventional therapies, and indicate its potential in managing Th1/Th2-mediated comorbidities. However, larger studies are needed to confirm these results.